KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Change in Receivables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Change in Receivables for 17 consecutive years, with $697.7 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 10.38% to $697.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 billion through Dec 2025, up 4.05% year-over-year, with the annual reading at $2.7 billion for FY2025, 4.05% up from the prior year.
  • Change in Receivables for Q4 2025 was $697.7 million at Bio-Rad Laboratories, up from $653.8 million in the prior quarter.
  • The five-year high for Change in Receivables was $728.6 million in Q2 2021, with the low at $627.2 million in Q2 2024.
  • Average Change in Receivables over 5 years is $674.0 million, with a median of $669.4 million recorded in 2022.
  • The sharpest move saw Change in Receivables surged 30.54% in 2021, then decreased 10.72% in 2022.
  • Over 5 years, Change in Receivables stood at $709.3 million in 2021, then grew by 1.15% to $717.4 million in 2022, then dropped by 5.68% to $676.7 million in 2023, then fell by 6.59% to $632.1 million in 2024, then grew by 10.38% to $697.7 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $697.7 million, $653.8 million, and $664.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.